Key points are not available for this paper at this time.
Altogether, our findings are of high clinical importance as we discovered that two clinically advanced AXL inhibitors, bemcentinib and gilteritinib, may display AXL-independent cellular effects and toxicity.
Johnson et al. (Fri,) studied this question.